000300772 001__ 300772
000300772 005__ 20250523114657.0
000300772 0247_ $$2doi$$a10.1016/j.xcrm.2025.102095
000300772 0247_ $$2pmid$$apmid:40315846
000300772 0247_ $$2altmetric$$aaltmetric:176678989
000300772 037__ $$aDKFZ-2025-00920
000300772 041__ $$aEnglish
000300772 082__ $$a610
000300772 1001_ $$aLaBelle, Jenna J$$b0
000300772 245__ $$aDissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure.
000300772 260__ $$aCambridge, MA$$bCell Press$$c2025
000300772 3367_ $$2DRIVER$$aarticle
000300772 3367_ $$2DataCite$$aOutput Types/Journal article
000300772 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747993585_12219
000300772 3367_ $$2BibTeX$$aARTICLE
000300772 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300772 3367_ $$00$$2EndNote$$aJournal Article
000300772 500__ $$aVolume 6, Issue 5, 20 May 2025, 102095
000300772 520__ $$aPediatric high-grade gliomas (pHGGs) are among the most lethal childhood tumors. While therapeutic approaches were largely adapted from adult treatment regime, significant biological differences between pediatric and adult gliomas exist, which influence the immune microenvironment and may contribute to the limited response to current pHGG treatment strategies. We provide a comprehensive transcriptomic analysis of the pHGG immune landscape using single-cell RNA sequencing and spatial transcriptomics. We analyze matched malignant, myeloid, and T cells from patients with pediatric diffuse high-grade glioma (HGG) or high-grade ependymoma, examining immune microenvironment distinctions after chemo-/radiotherapy, immune checkpoint inhibition treatment, and by age. Our analysis reveals differences in the proportions of pediatric myeloid subpopulations compared to adult counterparts. Additionally, we observe significant shifts toward immune-suppressive environments following cancer therapy. Our findings offer valuable insights into potential immunotherapy targets and serve as a robust resource for understanding immune microenvironmental variations across HGG age groups and treatment regimens.
000300772 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000300772 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300772 650_7 $$2Other$$aimmuno-oncology
000300772 650_7 $$2Other$$apediatric high-grade glioma
000300772 650_7 $$2Other$$asingle-cell RNA-seq
000300772 650_7 $$2Other$$atumor microenvironment
000300772 650_7 $$2Other$$atumor-infiltrating immune cell biology
000300772 7001_ $$aHaase, Rebecca D$$b1
000300772 7001_ $$aBeck, Alexander$$b2
000300772 7001_ $$aHaase, Jacob$$b3
000300772 7001_ $$aJiang, Li$$b4
000300772 7001_ $$aOliveira de Biagi, Carlos Alberto$$b5
000300772 7001_ $$aNeyazi, Sina$$b6
000300772 7001_ $$aEnglinger, Bernhard$$b7
000300772 7001_ $$aLiu, Ilon$$b8
000300772 7001_ $$aTrissal, Maria$$b9
000300772 7001_ $$aJeong, Daeun$$b10
000300772 7001_ $$aHack, Olivia A$$b11
000300772 7001_ $$aNascimento, Andrezza$$b12
000300772 7001_ $$aShaw, McKenzie L$$b13
000300772 7001_ $$aNguyen, Cuong M$$b14
000300772 7001_ $$aCastellani, Sophia$$b15
000300772 7001_ $$aMathewson, Nathan D$$b16
000300772 7001_ $$aAshenberg, Orr$$b17
000300772 7001_ $$aVeiga Cruzeiro, Gustavo Alencastro$$b18
000300772 7001_ $$aRosenberg, Tom$$b19
000300772 7001_ $$aVogelzang, Jayne R$$b20
000300772 7001_ $$aPyrdol, Jason$$b21
000300772 7001_ $$aMarx, Sascha$$b22
000300772 7001_ $$aLuomo, Adrienne M$$b23
000300772 7001_ $$aGodicelj, Anze$$b24
000300772 7001_ $$aBaumgartner, Alicia$$b25
000300772 7001_ $$aRozowsky, Jacob S$$b26
000300772 7001_ $$aMadlener, Sibylle$$b27
000300772 7001_ $$aMayr, Lisa$$b28
000300772 7001_ $$aPeyrl, Andreas$$b29
000300772 7001_ $$aGeyeregger, Rene$$b30
000300772 7001_ $$aLoetsch, Daniela$$b31
000300772 7001_ $$aDorfer, Christian$$b32
000300772 7001_ $$aHaberler, Christine$$b33
000300772 7001_ $$aStepien, Natalia$$b34
000300772 7001_ $$aSlavc, Irene$$b35
000300772 7001_ $$aDavidson, Tom Belle$$b36
000300772 7001_ $$aPrins, Robert M$$b37
000300772 7001_ $$aYeo, Kee Kiat$$b38
000300772 7001_ $$aCooney, Tabitha$$b39
000300772 7001_ $$aLigon, Keith$$b40
000300772 7001_ $$aLidov, Hart$$b41
000300772 7001_ $$aAlexandrescu, Sanda$$b42
000300772 7001_ $$aBaird, Lissa C$$b43
000300772 7001_ $$0P:(DE-He78)a975a4d7d3d59cc6ecc829e98bfe0c15$$aGojo, Johannes$$b44$$udkfz
000300772 7001_ $$aWucherpfennig, Kai W$$b45
000300772 7001_ $$aFilbin, Mariella G$$b46
000300772 773__ $$0PERI:(DE-600)3019420-9$$a10.1016/j.xcrm.2025.102095$$gp. 102095 -$$n5$$p102095$$tCell reports / Medicine$$v6$$x2666-3791$$y2025
000300772 909CO $$ooai:inrepo02.dkfz.de:300772$$pVDB
000300772 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a975a4d7d3d59cc6ecc829e98bfe0c15$$aDeutsches Krebsforschungszentrum$$b44$$kDKFZ
000300772 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000300772 9141_ $$y2025
000300772 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL REP MED : 2022$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:51:29Z
000300772 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:51:29Z
000300772 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:51:29Z
000300772 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCELL REP MED : 2022$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-05
000300772 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-05
000300772 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000300772 980__ $$ajournal
000300772 980__ $$aVDB
000300772 980__ $$aI:(DE-He78)B062-20160331
000300772 980__ $$aUNRESTRICTED